Clinical Trial Update: VB-111 in Surgically Accessible Recurrent/Progressive GBM [Phase 2]

View source ↗

Summary

Phase 2 trial of VB-111 in surgically accessible recurrent/progressive glioblastoma was terminated, with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• VB-111

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma, Recurrent Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2025-06-10